4CPS-110 Impact of patients’ conditions on the effectiveness and safety of erlotinib in pancreatic cancer

BACKGROUND: In post-PA studies in the use of erlotoinib, it was observed that the favourable clinical situation benefited the response to treatment. PURPOSE: To compare the effectiveness and safety of erlotinib, according to the Eastern Cooperative Oncology Group (ECOG), in pancreatic cancer. MATERI...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Eur J Hosp Pharm
Auteurs principaux: García, I Muñoz, Martínez-Penella, M, Mira-Sirvent, MC, Núñez-Bracamonte, S, Conesa-Nicolás, E, Viney, AC, Juez-Santamaria, C, Lloret-Llorca, A, García-Márquez, A, García-Lagunar, MH, Gutiérrez-Cívicos, MDR
Format: Artigo
Langue:Inglês
Publié: BMJ Group 2018
Sujets:
Section 4: Clinical pharmacy services
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535307/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.201
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires